Showing results (1001-1010 of 1,192) with videos related to
Sort By:
Pageof 120
Hemasphere|February 16, 2026
Outcomes of therapy-related non-core binding factor acute myeloid leukemia with venetoclax-based therapiesJayastu Senapati, Jennifer Croden, Guillermo Garcia-Manero, et al.Cancer|July 22, 2014
Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL)Michael E Rytting, Deborah A Thomas, Susan M O'Brien, et al.Journal of Hematology & Oncology|January 30, 2022
Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposureNicholas J Short, Sangeetha Venugopal, Wei Qiao, et al.Journal of the National Comprehensive Cancer Network : JNCCN|January 15, 2011
NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromesPeter L Greenberg, Eyal Attar, John M Bennett, et al.Blood Advances|April 22, 2021
Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclaxCurtis A Lachowiez, Sanam Loghavi, Ken Furudate, et al.Blood Cancer Journal|March 31, 2025
Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched studyAlex Bataller, Koji Sasaki, Samuel Urrutia, et al.The Lancet. Oncology|August 29, 2017
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trialHagop M Kantarjian, Gail J Roboz, Patricia L Kropf, et al.Frontiers in Immunology|February 8, 2021
Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary ComplicationsSang T Kim, Ajay Sheshadri, Vickie Shannon, et al.The Lancet. Haematology|July 22, 2024
Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trialMatteo Giovanni Della Porta, Guillermo Garcia-Manero, Valeria Santini, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2023
Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid MalignanciesJayastu Senapati, Warren C Fiskus, Naval Daver, et al.Pageof 120